Tag Archives: ampligen
Ampligen – AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection
Clinical Trial Arena: AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection, 7 January 2021 AIM ImmunoTech has dosed its first Covid-19 ‘long hauler’ patient in the active AMP-511 Expanded Access Program (EAP) with the Ampligen (rintatolimod) … Continue reading
Effect of disease duration in a randomized phase III trial of rintatolimod, an immune modulator for ME/CFS
Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, by David R Strayer, Diane Young, William M Mitchell in PLoS ONE 15(10): e0240403, Oct 29 2020 [doi.org/10.1371/journal.pone.0240403] Research … Continue reading
Ampligen – the first drug approved in the world for ME/CFS
Health rising blog post, by Cort Johnson, 25 August, 2016: Ampligen Takes Big Step Forward – Becomes First Drug Approved Anywhere For Chronic Fatigue Syndrome Ampligen became the first drug approved for chronic fatigue syndrome (ME/CFS) anywhere in the world … Continue reading
Efficacy of rintatolimod (Ampligen) in CFS/ME
Review abstract: Chronic fatigue syndrome/ Myalgic encephalomyelitis (CFS/ME) is a poorly understood seriously debilitating disorder in which disabling fatigue is an universal symptom in combination with a variety of variable symptoms. The only drug in advanced clinical development is rintatolimod, … Continue reading
Characteristics of CFS/ME sub-group who respond to Rintatolimod (Ampligen)
Research abstract: Background: Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a debilitating disease of unknown pathogenesis consisting of a variety of flu-like symptoms including severe fatigue. Initial analysis of the use of rintatolimod (Poly I: Poly C12U), a selective TLR3 agonist, … Continue reading
Ampligen trial shows benefits for long-standing debilitating CFS
A major study on the effects of Ampligen (Rintatolimod) on CFS provides added proof of Ampligen’s efficacy in ME/CFS following America’s Food & Drug Administration’s refusal to approve Ampligen for CFS in Dec 2009. 234 subjects with long-standing, debilitating CFS … Continue reading
